Didanosine
- Generic Name
- Didanosine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N4O3
- CAS Number
- 69655-05-6
- Unique Ingredient Identifier
- K3GDH6OH08
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse tra...
- Indication
For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 198
- Registration Number
- NCT00000851
- Locations
- 🇺🇸
Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States
🇺🇸St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States
🇺🇸Cook County Hosp., Chicago, Illinois, United States
A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 400
- Registration Number
- NCT00000770
- Locations
- 🇺🇸
Saint Clare's Hosp and Health Ctr, New York, New York, United States
🇺🇸Cornell Univ Med Ctr, New York, New York, United States
🇺🇸Summitt Med Ctr / San Francisco Gen Hosp, Oakland, California, United States
A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 1292
- Registration Number
- NCT00000781
- Locations
- 🇺🇸
Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States
🇺🇸Univ of Pennsylvania at Philadelphia, Philadelphia, Pennsylvania, United States
🇵🇷Univ of Puerto Rico, San Juan, Puerto Rico
Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 80
- Registration Number
- NCT00000657
- Locations
- 🇺🇸
San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States
Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00001048
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 400
- Registration Number
- NCT00000969
- Locations
- 🇺🇸
Comprehensive AIDS Alliance of Detroit, Detroit, Michigan, United States
🇺🇸Hill Health Corp, New Haven, Connecticut, United States
🇺🇸Wilmington Hosp / Med Ctr of Delaware, Wilmington, Delaware, United States
A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 15
- Registration Number
- NCT00000742
- Locations
- 🇺🇸
Univ. of Rochester ACTG CRS, Rochester, New York, United States
🇺🇸Washington U CRS, Saint Louis, Missouri, United States
🇺🇸USC CRS, Los Angeles, California, United States
Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy
- Conditions
The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 140
- Registration Number
- NCT00001074
- Locations
- 🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00001114
- Locations
- 🇺🇸
Bmc Actg Crs, Boston, Massachusetts, United States
🇺🇸Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
🇵🇷Puerto Rico-AIDS CRS, San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.